Depomed — Investor Presentation (March 2016)
29 slides from Depomed's investor presentation, Mar 14, 2016
Slide 1: Forward-Looking Statements
Forward-Looking Statements The statements that are not historical facts contained in this presentation are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed’s strategy, plans, objectives, expectations (financial or otherwise) and
Slide 2: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
March 2016 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Billion-dollar Blockbuster Opportunity (1) NUCYNTA re-launch improved promotion, positioning, pricing and proper dosing Expected blockbuster with >$1 Billion in annual sales before patent expiry (1) Strong Product
Slide 3: Depomed's Track Record of Successful Deals Builds Value
Reworked Santarus deal and tripled net revenue 34% revenue growth Q4 2015 over Q4 2014 Acquired Q4 2013; relaunched Q1 2014; 26% revenue growth Q4 2015 over Q4 2014 Q3 2011 Q4 2011 Q4 2013 TYPE 2 DIABETES DEAL Non-strategic milestones & royalties sold for $240 million Q4 2013 Relaunch Q4 2013 follow
Slide 4: Execution of Business Model Driving Triple Digit Growth in Sales and Profitability
Depomed’s Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability $500K $27.1M $58.1M $114M $485M-$525M (1) March 2016 2016 Total Revenue Guidance Adjusted EBITDA (Midpoint of adjusted EBITDA Guidance) $190M Two Ways to Grow: Organic Growth and Acquisition Tota
Slide 5: Consolidated Condensed Balance Sheet
Consolidated Condensed Balance Sheet 6 March 2016 Cash, cash equivalents and marketable securities $ 209,768 $ 566,402 Accounts receivable 71,687 28,078 Inventories 10,494 8,456 Income taxes receivable 6,358 4,030 Property and equipment, net 14,794 7,055 Intangible assets, net 1,008,994 72,361 Defer
Slide 6: Revenue Table
Revenue Table 7 March 2016 Product sales, net: Nucynta products $ 68,260 $ - $ 189,853 (1) $ - Gralise 21,737 18,110 81,054 60,411 Cambia 8,157 6,266 27,426 21,681 Lazanda 5,236 2,665 17,712 6,972 Zipsor 7,668 6,843 25,705 25,155 Total product sales, net 111,059 33,884 341,750 114,219 Royalties $ 11
Slide 7: Reconciliations of GAAP Reported to Non-GAAP Adjusted Information
Reconciliations of GAAP Reported to Non-GAAP Adjusted Information 8 March 2016 Total revenues 111,172 (488) (a) 110,684 194,601 (146,956) (a) 47,645 Cost of sales 21,007 (47) (b) 20,960 3,246 (118) (b) 3,128 Research and development expense 6,340 (58) (c) 6,282 2,033 (84) (c) 1,949 Acquired in-proce
Slide 8: Reconciliations of GAAP Reported to Non-GAAP Adjusted Information
Reconciliations of GAAP Reported to Non-GAAP Adjusted Information 9 March 2016 Total revenues 342,735 9,977 (a) 352,712 405,009 (242,808) (a) 162,201 Cost of sales 67,898 (6,044) (b) 61,854 15,146 (5,010) (b) 10,136 Research and development expense 17,541 (277) (c) 17,264 7,116 (258) (c) 6,858 Acqui
Slide 9: 2016 Financial Guidance
2016 Financial Guidance Total Revenue $485 to $525 million Total Non-GAAP SG&A Expense $180 to $195 million Total Non-GAAP R&D Expense $30 to $40 million Non-GAAP Adjusted Earnings $95 to $115 million Non-GAAP Adjusted EBITDA $175 to $205 million 10 March 2016 The Company expects Q1 2016 Revenues to
Slide 10: NUCYNTA Leading The Latest Chapter of Depomed's Growth Story
NUCYNTA Leading The Latest Chapter of Depomed’s Growth Story – Blockbuster Potential (1) Adds significant revenue and earnings to an already strong business Only new chemical entity in CII space approved by FDA in last 30 years Differentiated in multi-billion dollar pain market Exclusivity expected
Slide 11: NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales
Depomed’s NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales (1) March 2016 Proper Dosing Pricing and Access Positioning Promotion Significantly increased promotion and marketing efforts Revamped product positioning and messaging Maximize brand through pricing and access strategies E
Slide 12: Promotion: Significantly Increased to Drive Prescriptions and Market Share
Promotion: Significantly Increased to Drive Prescriptions and Market Share 13 March 2016 Increased Sales Force 1 Optimized Medical Education Identifying Appropriate Target Prescribers Promotion strategy consists of: 3-fold increase to 277 reps Highly experienced in pain and neurology Resumed full me
Slide 13: Promotion Progress: Accelerating Demand - Rx Growth of 11.9%
Sales force delivering approximately 10k NUCYNTA calls per week since re-launch NUCYNTA ER prescriptions reached an all-time monthly high of 30,622 in December 2015 Year-over-Year Rx growth now 11.9%, up from 3.4% in just 8 months 14 March 2016 Promotion Progress: Accelerating Demand - Rx Growth of
Slide 14: Positioning: Only FDA Approved Product Addressing Nociceptive and Neuropathic Pain
Positioning: Only FDA Approved Product that Addresses Both Nociceptive and Neuropathic Pain 15 March 2016 Chronic pain affects 1/3 of the US population More than 100 million adults with chronic pain 31 million with chronic lower back pain (CLBP) Potential significant impact from even modest uptick i
Slide 15: Positioning Progress: Market Share Increased From 1.49% to 1.77%
Competes in >$5 billion dollar Long Acting Opioid (LAO) market Increased promotional activities with new messaging resonating with prescribers Key opinion leaders educating on potential dual mechanism and titration Market share of LAO market up .28 in just 8 months 16 March 2016 Positioning Progress
Slide 16: Pricing and Access: Maximizing Brand Through Pricing and Access Strategies
Pricing and Access: Maximizing Brand Through Pricing and Access Strategies 17 March 2016 94% of commercial lives have access to NUCYNTA and NUCYNTA ER 3 Now approximately equivalent to OxyContin on a daily basis Adjusted Pricing Managed Care Dynamics Equivalent WAC ($/day) United Healthcare Commerci
Slide 17: Proper Dosing: Education on Titration is Key
Proper Dosing: Education on Titration is Key Average dose in low back pain trials was ~400mg/day after titration 18 March 2016 4 200 mg Proper Dose May Improve Physician and Patient Experience as well as Increase Average Selling Price Expert Opin. Pharmacother. (2010) 11(11):1787-1804 250 mg ~400 mg
Slide 18: NUCYNTA Patent Protection Expected to Provide Market Exclusivity
NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More (1) March 2016 February 2023: Expiry of patents covering tapentadol (composition of matter plus pediatric extension) December 2025: Expiry of polymorph patent (composition of matter plus pediatric extension) 2028:
Slide 19: Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth
Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time March 2016 Product Expected Exclusivity 2032+ Patents to 2032 Eligible for 5-year patent term extension 2028 3 primary patents, including composition of matter; ANDA suit pending 2024 Beat Actavis in U.S. Distri
Slide 20: Gralise Moving Toward $100 Million per Year
March 2016 Depomed’s Ability to Efficiently Execute and Deliver Growth - Gralise Reacquired marketing rights March 2011 and received $40M payment Launched in Q4 2011 >$86 million run rate as of Q4 2015 Market exclusivity expected until 2024; won District Court decision vs. first filer, Actavis; appe
Slide 21: CAMBIA Demonstrates Acquire, Integrate and Grow Strategy
March 2016 Depomed’s Ability to Efficiently Execute and Deliver Growth - CAMBIA Acquired in December 2013 for $48.7M Relaunched in Q1 2014 >$32 million run rate as of Q4 2015 Only single agent in its therapeutic class approved in the U.S. for treatment of acute migraine attacks in adults Exclusivity
Slide 22: Lazanda Continues Growth Trajectory
March 2016 Depomed’s Ability to Efficiently Execute and Deliver Growth - Lazanda Acquired in July 2013 for $4M Relaunched in Q4 2013 $21 million run rate as of Q4 2015 Only branded rapid acting fentanyl on Express Script Preferred National Formulary Depomed’s Lazanda Continues Growth Trajectory 24
Slide 23: Cebranopadol – Late-Stage, Novel, First-in-Class Potent Analgesic
March 2016 Cebranopadol – Late-Stage, Novel, First-in-Class Potent Analgesic Novel, First-In-Class Asset Acquired December 2015 to build on leading position in pain and neurology Unique dual mechanism-of-action that incorporates novel pharmacology: nociceptin/orphanin peptide (NOP) receptor agonist
Slide 24: Cebranopadol: Potency and Efficacy versus Morphine in Preclinical Models
Cebranopadol: Potency and Efficacy versus Morphine in Preclinical Models of Analgesia 26 Cebranopadol Morphine J Pharmacol Exp Ther 349:535–548, June 2014 March 2016
Slide 25: Cebranopadol: Phase IIb Trial in Chronic Lower Back Pain
Cebranopadol: Phase IIb Trial in Chronic Lower Back Pain (cLBP) Design 635 patients with moderate to severe cLBP 12-week, randomized, double-blind, placebo- and active-controlled, five-arm, monotherapy trial Efficacy, safety, and tolerability of once daily orally administered cebranopadol at three f
Slide 26: Acquire, Integrate and Grow Strategy Will Continue to Create Value
March 2016 We Expect Depomed’s “Acquire, Integrate and Grow” Strategy will Continue to Create Value Maintain pain and neurology focus, leveraging management’s expertise Products with current annual revenue between $20-$200MM+ Targeting products with lengthy exclusivity and future peak sales, markete
Slide 27: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
March 2016 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Billion-dollar Blockbuster Opportunity (1) NUCYNTA re-launch improved promotion, positioning, pricing and proper dosing Expected blockbuster with >$1 Billion in annual sales before patent expiry (1) Strong Product
Slide 28: Depomed — A Force in Pain and Neurology, in a Period of Accelerated Growth
Depomed —A Force in Pain and Neurology, in a Period of Accelerated Growth Billion-dollar Blockbuster Opportunity ( NUCYNTA re-launch improved promotion, positioning, pricing and proper dosing Expected blockbuster with >$1 Billion in annual sales before patent expiry ( Six branded, differentiated pro
Slide 29: Thank You
pve KS < Depomed Thank You www.depomed.com